This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Category: Funding
-
ATI secured funding from Mitsubishi UFJ Capital Co., Ltd
ATI is pleased to announce that our initial financing from Mitsubishi UFJ Capital (MUCAP) has been successfully closed. ATI will complete the master cell bank process to begin manufacturing of ATI-235, our lead asset in fibrosis, with IPF as the lead indication. Using the GLP manufactured antibody, ATI will complete the final preclinical process, safety/toxicity…